bpc 157 fda warning 2024 2025 FDA's Overreach on Compounded Peptides fda warning letter bpc-157 unapproved
Description
It's not worth the risk
As a dual GIP/GLP-1 receptor agonist, it activates two metabolic pathways simultaneously, producing average weight loss of 20.9% in clinical trials
Extra weight can cause a myriad of health problems along with exacerbating other health issues not caused by the weight
These findings support the rationale for initiating formal human clinical trials [83]
Biguanides (metformin): Medications used to treat type 2 diabetes, metabolic syndrome, nonalcoholic fatty liver disease, and polycystic ovary syndrome can lead to decreased vitamin B12 absorption (5)
